Abstract
The effects of MPP+ (2.5–20 mg/kg) on the adrenal glands and heart were investigated in rats. At various periods after s.c. drug administration the rats were decapitated and tissue catecholamine levels were determined by means of HPLC with electrochemical detection. Adrenal dopamine (DA) levels were reduced at 2–8 h after MPP+ administration, but this decrease was followed by an elevation after 16 h and return to the control values after one week. Three successive injections of MPP+ caused a statistically significant elevation in adrenal DA, one day, with a tendency to elevation four and seven days after the last injection, whereas a severe (up to 96%) decrease in heart noradrenaline (NA) was found one day after the last injection. Seven days after the last injection a 50% depletion of NA in the heart was still observed. Pretreatment with GBR 12909 (30 mg/kg, 4 h) blocked the MPP+ (10 mg/kg, 2 h) induced reduction of adrenal DA levels, but at the same time GBR 12909 failed to block the effects of MPP+ in the heart. One day after three successive daily injections of MPP+ (10 mg/kg each), the DA-uptake inhibitor GBR 12909 (30 mg/kg, 6 h) could still induce an increase in adrenal DA.
MPP+ appears to lack persistent cytotoxic action in the adrenal medulla but rather to cause a transient inhibition of DA synthesis followed by a compensatory stimulation. The inhibition can be blocked by specific inhibitor of the DA-uptake mechanism, suggesting a direct effect of MPP+ taken up by adrenomedullary cells. The data obtained so far do not suggest any involvement of peripheral dopaminergic nerves in the action of MPP+ on the adrenal medulla. The long-lasting depletion of the heart NA, however, suggests a lesion of peripheral noradrenergic nerves.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Algeri S, Ambrosio S, Garofalo P, Gerli P (1987) Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. Eur J Pharmacol 141:309–312
Andersen PH (1989) The dopamine uptake inhibitor GBR 12909; selectivity and molecular mechanism of action. Eur J Pharmacol 166:493–504
Barbeau A, Dallaire L, Bun NT, Poirier J, Rucinska E (1985) Comparative behavioural, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens. Life Sci 37:1529–1538
Daniels AJ, Reinhard JF Jr (1988) Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 263:5034–5036
Darchen F, Scherman D, Desnos C, Henry J-P (1988) Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules. Biochem Pharmacol 37:4381–4387
Fuller RW, Hemrick-Luecke SK (1990) Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice. Toxicol Lett 54:253–262
Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol — Mol Pharmacol Sect 208:273–286
Kujacic M, Carlsson A (1993) Evidence for an increased catecholamine synthesis in rat adrenal glands following stimulation of peripheral dopamine receptors. J Neural Transm [GenSect] 92:73–79
Kujacic M, Svensson K, Löfberg L, Carlsson A (1990) Acute changes in dopamine levels in rat adrenal glands after administration of dopamine receptor agonists and antagonists. Eur J Pharmacol 177:163 -170
Kujacic M, Svensson K, Löfberg L, Carlsson A (1991) Dopamine receptors, controlling dopamine levels in rat adrenal glands — comparison with central dopaminergic autoreceptors. J Neural Transm [GenSect] 84:195–209
Milliken GA, Johnson DE (1984) Analysis of Messy data, vol I: Designed experiments. Lifetime Learning Publications, Belmont, California, p 33
Namura I, Douillet P, Sun JC, Pert A, Cohen RM, Chiueh CC (1987) MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurones. Eur J Pharmacol 136:31–37
Notter MFD, Kaniuki M, Felten SY, Hansen JT, Gash DM (1991) Effect of MPTP on primate chromaffin cells in vitro: relevance for adrenal medullary cell transplantation. Restor Neurol Neurosci 3:1–10
Pileblad E, Fornstedt B, Clark D, Carlsson A (1985) Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. J Pharm Pharmacol 37:707–712
Reinhard JF Jr, Diliberto EJ Jr, Viveros HO, Daniels AJ (1987) Subcellular compartmentalisation of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 84:8160–8164
Reinhard JF Jr, Diliberto EJ Jr, Daniels AJ (1989) Characterization of cellular transport, subcellular distribution and secretion of neurotoxicant 1-methyl-4-phenylpyridinium in bovine adrenomedullary cell cultures. J Neurochem 52:1253–1259
Reinhard JF Jr, Carmichael SW, Daniels AJ (1990) Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. J Neurochem 55:311–320
Snape BM, Pileblad E, Ekman A, Magnusson T, Carlsson A, Engel J (1988) The effects of 1-methyl-4-phenylpyridinium ion (MPP+) on the efflux and metabolism on endogenous dopamine in rat striatal slices. J Pharm Pharmacol 40:620–626
Author information
Authors and Affiliations
Additional information
Correspondence to: M. Kujacic at the above address
Rights and permissions
About this article
Cite this article
Kujacic, M., Carlsson, A. Effects of MPP+ on catecholamine levels in adrenal glands and heart of rats. Naunyn-Schmiedeberg's Arch Pharmacol 350, 245–251 (1994). https://doi.org/10.1007/BF00175029
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00175029